PUBLISHER: The Business Research Company | PRODUCT CODE: 1760700
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760700
Primary ciliary dyskinesia (PCD) is a rare inherited disorder that affects the normal function and structure of cilia, which are microscopic, hair-like structures found in the airways, ears, and reproductive tract. Understanding and diagnosing PCD is essential for managing symptoms early and improving quality of life through targeted therapies.
The main types of treatment for primary ciliary dyskinesia (PCD) include antibiotics, airway clearance therapies, surgical interventions, and other supportive therapies. Antibiotics help treat respiratory bacterial infections, prevent lung damage, and maintain airway health. PCD is diagnosed through various methods, such as genetic testing, imaging techniques, clinical evaluation, and lung function tests. The treatments are distributed through multiple channels, including direct sales, online pharmacies, third-party distributors, and retail pharmacies. End-users of PCD treatments include hospitals, specialty clinics, diagnostic laboratories, and other healthcare providers.
The primary ciliary dyskinesia (PCD) market research report is one of a series of new reports from The Business Research Company that provides primary ciliary dyskinesia (PCD) market statistics, including the primary ciliary dyskinesia (PCD) industry global market size, regional shares, competitors with the primary ciliary dyskinesia (PCD) market share, detailed primary ciliary dyskinesia (PCD) market segments, market trends, opportunities, and any further data you may need to thrive in the primary ciliary dyskinesia (PCD) industry. This primary ciliary dyskinesia (PCD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The primary ciliary dyskinesia market size has grown strongly in recent years. It will grow from $0.46 billion in 2024 to $0.50 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to increasing clinical confusion with other respiratory disorders, a greater reliance on symptomatic treatment, enhanced use of general respiratory therapies, expanded diagnosis based on exclusion methods, and a growing focus on cystic fibrosis, which often overshadowed primary ciliary dyskinesia.
The primary ciliary dyskinesia market size is expected to see strong growth in the next few years. It will grow to $0.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to growing awareness of rare respiratory diseases, improved availability of genetic testing, a rise in cases of chronic respiratory infections, better reimbursement policies, and the expansion of specialized diagnostic centers. Key trends in the forecast period include advancements in genetic sequencing technologies, the development of non-invasive diagnostic tools, increased research and development collaborations, innovations in airway clearance devices, and the integration of artificial intelligence in diagnostic imaging.
The growing demand for gene therapy is expected to accelerate the expansion of the primary ciliary dyskinesia (PCD) market. Gene therapy involves modifying or replacing faulty genes in a patient's cells to treat or prevent diseases. The demand for gene therapy has surged due to significant progress in genetic research, allowing for more precise treatments that target and correct genetic disorders at the molecular level, improving patient outcomes. In particular, gene therapy is being developed for Primary Ciliary Dyskinesia (PCD) to correct the genetic mutations responsible for defective cilia function in the respiratory system. This therapy aims to introduce healthy genes to restore normal ciliary movement, enhance mucus clearance, and reduce respiratory infections. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, reported that the number of gene therapy programs in Phase II clinical trials reached 260 by the second quarter of 2023, a 5% increase from the first quarter. This growing focus on gene therapy is driving the growth of the primary ciliary dyskinesia market.
Key players in the primary ciliary dyskinesia market are focusing on the development of innovative therapies, such as investigational mRNA-based treatments, to improve symptom management and enhance the quality of life for patients. mRNA-based therapeutics use messenger RNA (mRNA) to instruct cells to produce proteins that may treat or prevent diseases. This cutting-edge approach targets conditions at the molecular level, leading to personalized medicine. For instance, in June 2024, ReCode Therapeutics, Inc., a US-based biotechnology company, launched RCT1100, an investigational inhaled mRNA therapy. The therapy received orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating primary ciliary dyskinesia. RCT1100 aims to restore ciliary function by delivering DNAI1 mRNA directly to airway cells, addressing a critical unmet need for the estimated 45,000 individuals affected by PCD in the U.S., as there are currently no disease-modifying treatments or cures for this condition.
In October 2024, PCD Research, a UK-based charitable organization focused on primary ciliary dyskinesia research, partnered with the Nucleic Acid Therapy Accelerator (NATA) to advance therapies for primary ciliary dyskinesia. The collaboration aims to co-fund a grant dedicated to developing innovative treatments for PCD, a rare genetic disorder that impairs respiratory function. The partnership seeks to support groundbreaking research that will improve treatment options and outcomes for individuals affected by this progressive and debilitating condition. NATA is a UK-based research initiative specializing in nucleic acid therapeutics.
Major players in the primary ciliary dyskinesia (pcd) market are Centogene N.V., Nationwide Children's Hospital, Revvity Inc., Quest Diagnostics Incorporated, Children's Healthcare of Atlanta, Exact Sciences Corp., University Hospital Southampton, UT Health East Texas, Guy's and St Thomas' NHS Foundation Trust, National Jewish Health, Vanderbilt University Medical Center, UNC School of Medicine, Stanford Medicine, Mayo Foundation for Medical Education and Research, DNA Labs India Pvt. Ltd., Parion Sciences Inc., ReCode Therapeutics Inc., University Hospital Munster, UAB Health System, PCD Foundation.
North America was the largest region in the primary ciliary dyskinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary ciliary dyskinesia (PCD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the primary ciliary dyskinesia (PCD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary ciliary dyskinesia market consists of revenues earned by entities by providing services such as pulmonary rehabilitation, home healthcare services, and genetic counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary ciliary dyskinesia market includes sales of immunofluorescence microscopy, transmission electron tomography, and whole-exome sequencing kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified.)
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Primary Ciliary Dyskinesia (PCD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on primary ciliary dyskinesia (pcd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for primary ciliary dyskinesia (pcd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary ciliary dyskinesia (pcd) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.